Breast Cancer

Honelako gehiago

WWI: The Trenches

by Danna Gamboa

Portfolio for 615

by Denise Nepveux

Making Strides

by Vanessa Guzman

Community Supports in the Lower Mainland for Graduates with Down Syndrome (please note that fees can be covered by bursaries)

by Amanda Turcato

Breast Cancer

Recurrent/metastatic

Chemotherapy + targeted therapy

Docetaxel + carboplatin + trastuzumab +/- pertuzumab Q21 days x6 cycles (TCH or TCHP)

Doxorubicin + Cyclophosphamide Q14/21 days x4 cycles

paclitaxel + trastuzumab +/- pertuzumab x 1 year

SERM if premenopausal AI if postmenopausal

Early (Stage I/IIA/IIB)

TNBC

Pembrolizumab + paclitaxel + carboplatin

pembrolizumab + AC

pembrolizumab as maintenance

Dose dense AC

taxane

Surgery

HR+

Endocrine therapy +/- Chemotherapy

Chemotherapy + anti-HER2 therapy + Endocrine therapy

Chemo + anti-HER2 options

Docetaxel + carboplatin + trastuzumab +/- pertuzumab Q21 days x6 cycles (TCH+/-P)

trastuzumab +/- pertuzumab x1 year

paclitaxel + trastuzumab +/- pertuzumab x 1 year (pertuzumab if node positive)

Endocrine options

CD4K inhibitors

Ribociclib Abemaciclib palbociclib

Ovarian ablation/suppression

Oophorectomy LH releasing agents

Goserelin leuprolide triptorelin

AI (POSTmenopausal)

Anastrozole Letrozole Exemestane

SERM

Tamoxifen(PREmenopausal)

HR-

HER2+

Chemotherapy + Anti-HER2 therapy

HER2-

Chemotherapy

Chemotherapy options

Taxane based

Docetaxel + Cyclophosphamide Q21 days x4 cycles (TC)

Anthracycline based

Doxorubicin + Cyclophosphamide Q14/21 days x4 cycles (AC)

paclitaxel weekly x12 weeks